News | April 07, 2022
Indian pharma growth likely to moderate in FY23: ICRA
Headwinds related to pricing pressures and rising raw material costs will result in some contraction in margins in Q4 FY22 and FY23
Headwinds related to pricing pressures and rising raw material costs will result in some contraction in margins in Q4 FY22 and FY23
MilliporeSigma to become the first company to offer a fully integrated ecosystem for advanced process technologies
Highlighted as game changer in drug development & delivery special feature on innovative technologies for improving drug solubility and bioavailability
New high-throughput, no-wash assays contribute to the development, manufacture and quality control of safer, more effective biotherapeutics
R&D investment up 11.7% to 4.1 billion EUR in 2021 (20.0% of net sales)
Casper Pharma is a Hyderabad based SEZ company engaged in the formulations business. Post-purchase of shares, the target entity would become a wholly-owned subsidiary of SPL
The two-day event will showcase achievements and address issues pertaining to the industry
Intas has developed a biosimilar of Lucentis, which is currently under Phase III global trial for submission in major countries including EMA & the US
WHO’s post EUA inspection found deficiencies in Good Manufacturing Practice at the facility
Primarily set up to address the Covid-19 emergency, the WHO technology transfer hub has the potential to expand manufacturing capacity for other products as well, including treatments, and target other priorities such as malaria, HIV and cancer
Subscribe To Our Newsletter & Stay Updated
